Xtant Medical Holdings Inc XTNT Stock Analysis
- NYSE American
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.29 down $0.02, 5.32% at close Oct 16
Last close · Previous close $0.30
- Market cap
- $40.21MAt the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.08Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.29down $0.03, 10.41%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.30Oct 15
- Volume97.84KOct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume156.70KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.27 to $0.95; now $0.29
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
XTNT trailed the S&P 500 in all 7 periods.
| Period | XTNT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XTNT: down 10.4% S&P 500: up 1.5% | XTNT trailed the S&P 500 by 11.9 percentage points Trailed |
| 3M | XTNT: down 35.3% S&P 500: up 1.9% | XTNT trailed the S&P 500 by 37.2 percentage points Trailed |
| YTD | XTNT: down 63.4% S&P 500: up 12.8% | XTNT trailed the S&P 500 by 76.2 percentage points Trailed |
| 1Y | XTNT: down 59.5% S&P 500: up 16.8% | XTNT trailed the S&P 500 by 76.3 percentage points Trailed |
| Long term | ||
| 3Y | XTNT: down 73.7% S&P 500: up 81.5% −35.9% vs +22.0% a year | XTNT trailed the S&P 500 by 155.2 percentage points Trailed |
| 5Y | XTNT: down 74.2% S&P 500: up 83.1% −23.7% vs +12.9% a year | XTNT trailed the S&P 500 by 157.3 percentage points Trailed |
| 10Y | XTNT: down 97.6% S&P 500: up 319.6% −31.2% vs +15.4% a year | XTNT trailed the S&P 500 by 417.2 percentage points Trailed |
$10,000 invested in XTNT 10 years ago (Oct 14, 2016) would be worth about $239 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
XTNT trailed the S&P 500 in all 7 periods.
| Period | XTNT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XTNT: down 10.4% S&P 500: up 1.2% | XTNT trailed the S&P 500 by 11.6 percentage points Trailed |
| 3M | XTNT: down 35.3% S&P 500: up 1.7% | XTNT trailed the S&P 500 by 37.0 percentage points Trailed |
| YTD | XTNT: down 63.4% S&P 500: up 11.9% | XTNT trailed the S&P 500 by 75.3 percentage points Trailed |
| 1Y | XTNT: down 59.5% S&P 500: up 15.5% | XTNT trailed the S&P 500 by 75.0 percentage points Trailed |
| Long term | ||
| 3Y | XTNT: down 73.7% S&P 500: up 75.0% −35.9% vs +20.5% a year | XTNT trailed the S&P 500 by 148.7 percentage points Trailed |
| 5Y | XTNT: down 74.2% S&P 500: up 71.2% −23.7% vs +11.4% a year | XTNT trailed the S&P 500 by 145.4 percentage points Trailed |
| 10Y | XTNT: down 97.6% S&P 500: up 258.1% −31.2% vs +13.6% a year | XTNT trailed the S&P 500 by 355.7 percentage points Trailed |
$10,000 invested in XTNT 10 years ago (Oct 14, 2016) would be worth about $239 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$42.12
Closing high on . Now 99.3% below that record.
Split-adjusted daily closes since Oct 19, 2015.
Stock splits
1
1-for-12 on . Share counts adjust after each split.
Valuation
The Oct 16 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$0.08 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. When XTNT was profitable over the past five years, its P/E ranged from 15.3× to 252.3×, with a median of 51.4×. How to read P/E
Other valuation measures
- 0.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - 1.0×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −1.14%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $56.01MAt the Oct 16 close
What it would cost to buy the whole business: the market cap at the Oct 16 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own XTNT DCF in Excel. Value Xtant Medical Holdings with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $109.53Mdown 14.3%
- Net income
- −$11.14M
- Diluted EPS
- −$0.08
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $27.94M | −$5.02M | −$0.04 |
| Q4 FY24 (Dec 31, 2024) | $31.51M | −$3.17M | −$0.02 |
| Q1 FY25 (Mar 31, 2025) | $32.90M | $58.00K | $0.00 |
| Q2 FY25 (Jun 30, 2025) | $35.41M | $3.55M | $0.03 |
| Q3 FY25 (Sep 30, 2025) | $33.26M | $1.31M | $0.01 |
| Q4 FY25 (Dec 31, 2025) | $32.36M | $57.00K | $0.00 |
| Q1 FY26 (Mar 31, 2026) | $20.88M | −$3.09M | −$0.02 |
| Q2 FY26 (Jun 30, 2026) | $23.03M | −$9.41M | −$0.07 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $55.26M | −$4.85M | −$0.06 |
| FY22 (Dec 31, 2022) | $57.97M | −$8.49M | −$0.09 |
| FY23 (Dec 31, 2023) | $91.30M | $660.00K | $0.01 |
| FY24 (Dec 31, 2024) | $117.27M | −$16.45M | −$0.12 |
| FY25 (Dec 31, 2025) | $133.93M | $4.97M | $0.04 |
Margins
- Gross 59.4%
- Operating −9.6%
- Net −10.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$459.00KLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$570.00KLast 12 months
- Capital spending$1.03MLast 12 months
- −0.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $65.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$65.00KLast 12 months
Balance sheet
- $10.22MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$26.01MAs of Jun 30, 2026
- Net debt$15.80MAs of Jun 30, 2026
- 2.16As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.65As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −23.5%Last 12 months
Over the last 12 months, Xtant Medical Holdings lost money: its net loss was 23.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −12.4%Last 12 months
Over the last 12 months, Xtant Medical Holdings’s net loss was 12.4% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Xtant Medical Holdings Inc
Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. ( www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Montana, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE American
- Asset type
- Common stock
- Price history since
XTNT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
XTNT stock FAQ
What is XTNT stock’s price today?
Xtant Medical Holdings (XTNT) traded at $0.29 at the close on , down $0.02 (5.32%) from the previous close of $0.30. Over the past 52 weeks it has traded between $0.27 and $0.95.
If you invested $1,000 in XTNT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in XTNT on would be worth about $24 at the close on , a total return of −97.6%. The same $1,000 would be worth $258 if invested five years ago and $405 if invested one year ago. Past performance doesn’t predict future returns.
What is Xtant Medical Holdings’s market cap?
Xtant Medical Holdings’s market capitalization is about $40.2 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $0.29 (how market cap works). Xtant Medical Holdings reported 140.26M shares outstanding at the end of its latest quarter ().
What is XTNT’s P/E ratio?
XTNT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.08). When it was profitable over the past five years, its P/E ranged from 15.3 to 252.3.
How much revenue does Xtant Medical Holdings make?
Xtant Medical Holdings reported $109.5 million of revenue over the four quarters to , down 14.3% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $23.0 million, down 35.0% from a year earlier.
Is Xtant Medical Holdings profitable?
Not over the four quarters to . Xtant Medical Holdings reported a net loss of $11.1 million across those four quarters on $109.5 million of revenue.
What are XTNT’s earnings per share?
XTNT’s diluted earnings per share were −$0.08 over the four quarters to , compared with −$0.03 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.07 per share, against $0.03 a year earlier (how EPS works).
Does XTNT pay a dividend?
Xtant Medical Holdings hasn’t paid a dividend in the last twelve months.
What is XTNT’s 52-week high and low?
Over the past 52 weeks XTNT has traded as low as $0.27 and as high as $0.95. At $0.29 at the close on , it is 69.8% below that high and 6.1% above the low.
What is XTNT’s all-time high?
XTNT’s highest closing price was $42.12 on , adjusted for stock splits. At $0.29 at the close on , it is 99.3% below that record.
Has XTNT stock ever split?
Yes, once: 1-for-12 on .
How has XTNT stock performed?
Including dividends and measured to the close on , XTNT has returned −63.4% so far this year and −59.5% over the past year, and −74.2% over five years (−23.7% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Xtant Medical Holdings in?
Xtant Medical Holdings is in the Healthcare sector and the Medical Devices industry, and is headquartered in Montana, USA.
What exchange does XTNT trade on?
Xtant Medical Holdings trades on the NYSE American under the ticker symbol XTNT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.